[EN] DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ENRICHIS EN DEUTÉRIUM EN TANT QU'INHIBITEURS DE KINASES
申请人:ASCEPION PHARMACEUTICALS INC
公开号:WO2012028106A1
公开(公告)日:2012-03-08
The present invention provides deuterium-enriched heteroaryl-containing urea compounds (I) and use of the same for treating conditions mediated by protein kinase such as
本发明提供了富含氘的杂环基脲化合物(I)以及利用这些化合物治疗由蛋白激酶介导的疾病的方法。
[EN] NOVEL CATHEPSIN C INHIBITORS AND THEIR USE<br/>[FR] NOUVEAUX INHIBITEURS DE LA CATHEPSINE C ET LEUR UTILISATION
申请人:GLAXO GROUP LTD
公开号:WO2009026197A1
公开(公告)日:2009-02-26
The invention is directed to compounds according to Formula (I) wherein R1, R2a, R2b, R2c, R3, and n are defined below, and to pharmaceutically-acceptable salts thereof. They are cathepsin C inhibitors and can be used in the treatment of diseases mediated by the cathepsin C enzyme, such as COPD.
[EN] DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE DIHYDRO-CYCLOPENTA-ISOQUINOLINE
申请人:UCB BIOPHARMA SRL
公开号:WO2021130255A1
公开(公告)日:2021-07-01
The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.
[EN] OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF<br/>[FR] COMPOSÉS OXYCARBAMOYLE ET LEUR UTILISATION
申请人:SHIONOGI & CO
公开号:WO2009151152A1
公开(公告)日:2009-12-17
The invention relates to oxycarbamoyl compounds of Formula I: The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockadeof calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.